Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700464 · ClinicalTrials.gov registry record · NA
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma
A NA study of Bladder Cancer, sponsored by Nucleix.
- Completed
- Registry status
- NA
- Development phase
- 680
- Enrollment target
- 11
- Study locations
NCT02700464 is a NA study of Bladder Cancer that has completed, run by Nucleix. The registered enrollment target is 680 participants, below the 12,750-participant average among 175 other Bladder Cancer trials with a reported enrollment target (95% lower). The trial reports 11 study locations across 11 states.
The verdict
NCT02700464, a NA study of Bladder Cancer, has completed, sponsored by Nucleix.
- COMPLETED
- Registry status
- NA
- Development phase
- 680 participants
- Enrollment target
- 11
- Study locations
Study Summary
Clinical trial to determine the efficacy (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology in patients under monitoring for recurrence of bladder cancer.
Conditions Studied
Interventions
- DEVICE Bladder EpiCheck Urine Test
- PROCEDURE Cystoscopy and pathology
Study Locations (11)
Colorado
- The Urology Center of Colorado - Denver
Maryland
- Chesapeake Urology Research Associates - Baltimore
Michigan
- Michigan Institute of Urology, P.C. - Troy
Minnesota
- Metro Urology - Woodbury
New York
- Urological Surgeons of Long Island - Garden City
North Carolina
- Duke University Health System - Durham
Ohio
- Cleveland Clinic - Cleveland
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2016-09 |
| Est. Completion | 2020-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02700464
The ClinicalTrials.gov registry entry for NCT02700464 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 680 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,750-participant average among 175 other Bladder Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Nucleix, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bladder EpiCheck Urine Test is the first listed.
NCT02700464 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Colorado, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT02700464 about?
NCT02700464 is a clinical study titled "The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma". Clinical trial to determine the efficacy (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology in patients under monitoring for recurrence of bladder cancer.
What is the current status of trial NCT02700464?
This trial is currently completed. It is a NA study. The enrollment target is 680 participants. The study started on 2016-09. Estimated completion is 2020-07.
What conditions does trial NCT02700464 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT02700464?
The interventions under investigation include: Bladder EpiCheck Urine Test (DEVICE), Cystoscopy and pathology (PROCEDURE).
Who is sponsoring clinical trial NCT02700464?
This trial is sponsored by Nucleix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02700464 being conducted?
This trial has 11 study locations across Colorado, Maryland, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.